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The risk of locoregional recurrence in resected gastric adenocarcinoma is high, but the benefit of adjuvant treatment remains
controversial. In particular, after extended lymph node dissection, the role of radiotherapy is questionable. Since 1995, we started a
clinical protocol of adjuvant chemoradiotherapy after D2 gastrectomy and analysed the patterns of failure for 291 patients. Adjuvant
chemotherapy consisted of five cycles of fluorouracil and leucovorin, and concurrent radiotherapy was given with 4500cGy from the
second cycle of chemotherapy. With a median follow-up of 48 months, 114 patients (39%) showed any type of failure, and the local
and regional failures were seen in 7% (20 out of 291) and 12% (35 out of 291), respectively. When the recurrent site was analysed
with respect to the radiation field, in-field recurrence was 16% and represented 35% of all recurrences. Our results suggest that
adjuvant chemoradiotherapy has a potential effect on reducing locoregional recurrence. Moreover, low locoregional recurrence rates
could give a clue as to which subset of patients could be helped by radiotherapy after D2 gastrectomy. However, in order to draw a
conclusion on the role of adjuvant radiotherapy, a randomised study is needed.
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Gastric cancer is the most common cancer in Korea (Shin et al,
2002). Complete tumour removal with sufficient resection margin
plus extended lymph node dissection is considered to be the most
important factor in terms of reduced locoregional recurrence and
improved survival. Although the incidence of early gastric cancer
is increasing, most patients still present with an advanced stage,
and, even after complete resection, 38–94% of patients developed
locoregional recurrence (McNeer et al, 1951; Gunderson and Sosin,
1982; Wisbeck et al, 1986; Landry et al, 1990), which translates into
33–69% of all recurrences (Gunderson and Sosin, 1982; Landry
et al, 1990; Maehara et al, 2000; Yoo et al, 2000). However, high
recurrence rates may be reduced by adjuvant treatment, so
postoperative adjuvant radiotherapy and/or chemotherapy is
generally performed.
There were several studies (GITSG, 1982; Moertel et al, 1984;
Allum et al, 1989; Regine and Mohiuddin, 1992) showing positive
effects of radiotherapy and/or chemotherapy in patients with
locally advanced or unresectable gastric adenocarcinoma, but the
benefit of adjuvant treatment after curative resection remains
controversial. Intergroup trial (MacDonald et al, 2001) showed that
adjuvant chemoradiotherapy reduced recurrences and increased
survival of patients with gastric adenocarcinoma. However, after
extended lymph node dissection with R0 gastrectomy, there are no
data regarding whether adjuvant radiotherapy could reduce
locoregional recurrence and increase survival.
The purpose of this study was to analyse the patterns of failure
in patients with gastric adenocarcinoma after gastrectomy with D2
lymph node dissection plus postoperative chemoradiotherapy, and
to evaluate any effect of adjuvant radiotherapy on locoregional
recurrence reduction and survival improvement.
MATERIALS AND METHODS
Patients
From 1995 to 1999, a total of 322 patients with curatively resected
gastric adenocarcinoma received adjuvant chemoradiotherapy at
the Samsung Medical Center. The eligibility criteria and the
postoperative adjuvant treatment used were the same as those used
for the SWOG-9008 (INT-0116) trial (MacDonald et al, 2001). All
patients had R0 gastrectomy and the extent of lymph node
dissection was more than D2 dissection. At 3–7 weeks after
surgery, chemotherapy with fluorouracil 400mgm
 2day
 1 and
leucovorin 20mgm
 2day
 1 was administered for 5 days, and this
was followed by chemoradiotherapy beginning 4 weeks after the
start of the first cycle of chemotherapy. The chemoradiotherapy
consisted of 4500cGy of radiation over 5 weeks, with fluorouracil
and leucovorin on the first 4 and last 3 days of radiotherapy. At 4
weeks after the completion of radiotherapy, two 5-day cycles of
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lchemotherapy with fluorouracil plus leucovorin were given 4
weeks apart. Initially, the pathologic stage was classified according
to the 1992 staging criteria of the American Joint Commission on
Cancer, but this was refined in accord with the 1997 AJCC staging
criteria. Informed consent was obtained from each individual
before enrolment and the study protocol was reviewed and
approved by the Samsung Medical Center Institutional Review
Board.
Radiotherapy plan
Radiation was targeted to the tumour bed, anastomosis site,
duodenal stump, remnant stomach and regional lymph nodes
(Figure 1). Other than for T4 lesions, the tumour bed was not
the radiotherapy target, because there was no microscopic
residuum after R0 gastrectomy. For the radiation of the
anastomosis site and duodenal stump, more than 2cm beyond
the proximal and distal resection margins was included within the
radiation field. In patients with subtotal gastrectomy, the remnant
stomach was included in the radiation field, but, if the volume of
the irradiated left kidney exceeded more than half of the whole left
kidney volume or if a patient could not tolerate the acute
gastrointestinal complications caused by the large radiation field,
the field was modified, and some of the remnant stomach was
excluded. To delineate regional lymph node areas, we used the
definition of the Japanese Research Committee for Gastric Cancer
(Kajitani, 1981). Although the irradiated node areas were modified
according to the primary tumour location, the radiation field
usually included more than group 2 lymph nodes. Anterior–
posterior parallel opposing fields were used and the radiation
dose was 4500cGy, with 180cGy daily fractions over 5 weeks. If
the proximal or distal resection margin was less than 2cm, a
boost radiotherapy of 1000cGy was delivered in daily fractions
of 200cGy.
Follow-up and definition of recurrence
After the completion of planned adjuvant treatment, regular
follow-up was carried out with physical examination, complete
blood count, liver function test, chest radiography, abdominopel-
vic computed tomography and gastroscopy. The follow-up
intervals were 3 months for the first year, 6 months for the next
2 years and yearly thereafter. During the follow-up period, any
suspected recurrence was confirmed pathologically, if possible,
and the first recurrence site was used to determine local
recurrence, regional recurrence, or distant metastasis. Local
recurrence was defined as recurrence at the anastomosis site,
duodenal stump, tumour bed, or remnant stomach. Regional
recurrence was defined as recurrence at the regional lymph nodes
within the radiation field. Distant metastasis was defined as lymph
node recurrence outside the radiation field, peritoneal seeding,
liver metastasis, or metastasis of other extra-abdominal sites. If
two or more failure sites developed at the same time, they were
counted separately.
Statistical methods
Relapse-free survival was defined as the time from surgery to the
first recurrence and overall and disease-free survival was estimated
by the Kaplan–Meier method. To determine relationships between
the patterns of recurrence and clinicopathological factors, the w
2
test was used. Independent risk factors that influenced recurrence
were analysed for by logistic regression analysis.
RESULTS
Patients’ characteristics
Of the 322 patients enrolled on the adjuvant chemoradiotherapy
protocol, 31 (10%) did not receive radiotherapy because of a poor
performance status, refusal of further treatment or disease
progression after the first cycle of chemotherapy. Therefore, 291
patients were analysed for survival and patterns of failure. The
median follow-up period for all patients was 48 (range 5–84)
months, and that of living patients was 60 (range 37–84) months.
The characteristics of the patients and their surgical results are
described in Tables 1 and 2. The numbers of dissected lymph node
were 10–114 (median, 35), and in 236 patients (81%) more than 25
lymph nodes were dissected. Lymph node metastasis developed in
90% of the patients (263 out of 291 patients). Eight patients (3%)
did not complete radiation therapy because of gastrointestinal
complications, such as nausea and diarrhoea in four patients, three
refused radiotherapy for personal reasons and one patient
developed distant metastasis during radiotherapy.
Toxicity
Toxicities were graded as 1–4 based on the Southwest Oncology
Group Toxicity Criteria. In terms of gastrointestinal complications,
nausea was the most common toxicity and 36 patients (12%)
experienced nausea graded as 3 or higher. Diarrhoea graded as 3 or
higher occurred in 30 patients (10%). Four patients did not
complete radiotherapy because of these gastrointestinal complica-
tions. During the follow-up period, intestinal fibrosis associated
with radiotherapy developed in one patient (Figure 2) and
intestinal obstructions not due to tumour recurrence occurred in
20 patients – 15 patients as grade 3 and five patients as grade 4.
The resection and re-anastomosis or adhesiolysis was performed
Figure 1 Radiation field of a patient with subtotal gastrectomy and
Billroth I anastomosis. The white solid line includes the tumour bed,
anastomosis site, remnant stomach and regional lymph nodes. RK¼right
kidney; LK¼left kidney.
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lin five patients (2%) with intestinal obstruction grade 4. In three of
these five patients, the bowel obstructive sites were outside the
radiation field. The most common hematologic complication was
neutropenia, and 90 patients (31%) had neutropenia graded as 3 or
higher. Thrombocytopenia graded as 3 or higher occurred in 15
patients (5%). No toxicity-related death occurred during follow-up
period.
Survival and relapse
The 5-year overall survival and disease-free survival rates were 62
and 58% (Figure 3). Figure 4 shows the 5-year survival rates
according to AJCC stage.
During the follow-up period, 114 patients (39%) relapsed at 156
sites and the median time to recurrence from surgery was 16
months (ranged 3–59 months). Of these patients, 77 patients had
one recurrence pattern – local recurrence in seven patients,
regional recurrence in three patients and distant metastasis in 67
patients, and 37 patients had recurrences at multiple sites
(Figure 5). Therefore, local recurrence, regional recurrence and
distant metastasis occurred in 20 patients (7% of all patients), 35
patients (12% of all patients) and 101 patients (35% of all patients),
respectively. Locoregional recurrence, defined as recurrence within
the radiation field, developed in 16% (47 out of 291) and
represented 35% of all recurrences. In all, 65% of recurrences
developed outside the radiation field and the most common
metastatic site was peritoneal seeding. Table 3 shows the specific
recurrence sites.
Prognostic factors for recurrence
To evaluate the prognostic factors of recurrence, variable
clinicopathological factors – sex, age, type of operation, location
of tumour, histological type (WHO classification, grade, Lauren
type), invasion depth of tumour, number of involved lymph node
and TNM stage – were analysed. The type of operation, the
location of tumour and its stage were prognostic factors for total
Table 1 Characteristics of the patients (n¼291)
Characteristics No. of patients (%)
Sex
Male 190 (65)
Female 101 (35)
Age
p60 210 (72)
460 81 (28)
ECOG performance score
0–1 279 (96)
2–3 12 (4)
Location of tumour
Distal 1/3 145 (50)
Middle 1/3 120 (41)
Proximal 1/3 23 (8)
Whole stomach 3 (1)
Type of operation
Total gastrectomy 116 (40)
Subtotal gastrectomy 175 (60)
Table 2 Postoperative results of patients (n¼291)
Characteristics No. of patients (%)
Histology
WHO classification
Adenocarcinoma
a 215 (74)
Mucinous 15 (5)
Signet ring cell 59 (20)
Undifferentiated 2 (1)
Grade
W/D 4 (1)
M/D 82 (28)
P/D 205 (70)
Lauren type
Intestinal 92 (32)
Diffuse 190 (65)
Mixed 9 (3)
Stage
b
T stage
T1 25 (9)
T2 116 (40)
T3 143 (49)
T4 7 (2)
N stage
N0 28 (10)
N1 135 (46)
N2 83 (29)
N3 45 (16)
AJCC
IB 35 (12)
II 72 (25)
IIIA 91 (31)
IIIB 46 (16)
IV (M0) 47 (16)
W/D¼well differentiated; M/D¼moderately differentiated; P/D¼poorly differen-
tiated.
aPapillary and tubular adenocarcinoma.
b1997 AJCC staging criteria.
Figure 2 Upper gastrointestinal radiograph of a patient who developed
intestinal radiation fibrosis. The black arrow indicates segmental narrowing
of the jejunal loop below the anastomosis site.
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lrecurrence, but sex, age and histological type were unrelated to
recurrence (Table 4). The TNM stage and the invasion depth of a
tumour (T stage) were found to correlate with all types of recurrent
patterns. The number of involved lymph nodes (N stage) did not
affect local recurrence, but did affect regional recurrence and
distant metastasis.
Logistic regression analysis showed that the independent risk
factors for total recurrence were tumour invasion to more than the
serosa, total gastrectomy, and lymph node metastasis. When each
recurrence site was separately analysed, no statistically significant
risk factor for local recurrence was identified. For regional
recurrence, total gastrectomy was the only risk factor, and for
distant metastasis tumour invasion to more than the serosa, lymph
node metastasis and total gastrectomy were risk factors.
DISCUSSION
To determine the role of postoperative adjuvant radiotherapy in
resected gastric adenocarcinoma, a comparative analysis of failure
patterns after curative resection with and without adjuvant
treatment is needed. The patterns of failure after curative resection
in gastric cancer have been reported on many occasions (McNeer
et al, 1951; Thomson and Robins, 1952; Wangensteen et al, 1954;
Gunderson and Sosin, 1982; Wisbeck et al, 1986; Landry et al,
1990; Yoo et al, 2000), and these studies show high levels of
locoregional recurrences after curative resection. However, we
should be cautious about accepting the results of these studies.
Many studies that reported high locoregional recurrences have
some drawbacks in terms of data comparisons. First, they had
different viewpoints of recurrence. For example, the results of
autopsy studies provide useful information about the recurrence,
but they reveal only the end patterns of failure after surgery
(McNeer et al, 1951; Thomson and Robins, 1952; Wisbeck et al,
1986). Reoperation data are highly selective, with a focus on high-
risk patients (Wangensteen et al, 1954; Gunderson and Sosin,
1982), and clinical studies contain relatively little information on
the exact incidence of recurrence, though they are useful for
assessing which subsets of patients may benefit from adjuvant
therapy (Papachristou and Fortner, 1981; Landry et al, 1990;
Maehara et al, 2000; Yoo et al, 2000). Second, the definition of
failure patterns differed, in particular, the definition of regional
recurrence. In the present study, we defined the regional
recurrence as recurrence at lymph nodes within the radiation
field, and the radiation field usually included more than group 2
lymph nodes. The lymph node recurrence outside the radiation
field was defined as distant metastasis. The definition of our study
accords with the concept that metastasis to group 3 lymph nodes
could be considered as distant metastasis. Third, the surgical
extent differed, especially with respect to the extent of lymph node
dissection. Though the effect of extended lymph node dissection
remains controversial between randomised studies (Dent et al,
1988; Bonenkamp et al, 1999; Cuschieri et al, 1999) and
retrospective studies (Kodama et al, 1981; Pacelli et al, 1993;
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Figure 3 Overall survival (5-year) and disease-free survival of all patients
(n¼291).
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Figure 4 Overall survival (5-year) according to AJCC stage.
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Figure 5 Patterns of failure in 114 patients: local recurrence in 20
patients, regional recurrence in 35 patients, distant metastasis in 101
patients.
Table 3 The recurrent sites (156 sites) of 114 patients
Recurrent site No. of patients (%)
Local failure 20 (7)
Anastomosis site 16
Remnant stomach 4
Duodenal stump 2
Regional failure 35 (12)
Distant metastasis 101 (35)
Peritoneal seeding 81
Liver metastasis 23
Pleura+lung parenchyma 11
Bone metastasis 7
Virchow’s node 6
Brain metastasis 2
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lSiewart et al, 1998), the extent of lymph node dissection may affect
regional recurrence, which causes confusion when we attempt to
determine the role of postoperative radiotherapy. Therefore, from
studies on patterns of failure after curative resection, we can obtain
useful but limited information about locoregional recurrence and
the determination of the radiotherapy target. Thus, in order to
determine the role of adjuvant radiotherapy in resected gastric
adenocarcinoma, a well-organised randomised study is needed. In
this respect, the results of the intergroup trial were encouraging.
MacDonald et al reported the results of a randomised trial. They
compared chemoradiotherapy after surgery with surgery alone in
adenocarcinoma of the stomach or gastroesophageal junction. This
was the only randomised study to compare adjuvant chemo-
radiotherapy with surgery alone. The study showed that overall
survival and relapse-free survival were superior in the adjuvant
chemoradiotherapy group, whereas the relapse rate was higher in
the surgery alone group. They concluded that postoperative
chemoradiotherapy should be considered for all patients with a
high risk of recurrence. This randomised study showed that
adjuvant chemoradiotherapy has a significant role in reducing
recurrence and increasing survival, and suggests that it could
become a standard treatment modality in resected gastric
adenocarcinoma. However, this result does not apply to all cases
of resected gastric adenocarcinoma. As only 10% of the patients of
intergroup trial had undergone D2 lymph node dissection, we have
limited information as to whether another locoregional modality
plays a role after a primary locoregional modality in gastric
adenocarcinoma with D2 gastrectomy. Therefore, we believe that it
is unreasonable to conclude that postoperative chemoradiotherapy
should be administered to patients with gastrectomy plus D2
lymph node dissection. Another considerable point concerns the
identity of the subset of patients at high risk of locoregional
recurrence. In many retrospective studies (Kodama et al, 1981;
Maruyama et al, 1989; Sasako et al, 1995), the invasion depth of the
primary tumour was found to influence the extent of lymph node
metastasis, so there is a possibility that not all stage patients would
benefit from adjuvant radiotherapy after extended lymph node
dissection.
Even after complete resection, 38–94% of patients developed
locoregional recurrence (McNeer et al, 1951; Gunderson and Sosin,
1982; Wisbeck et al, 1986; Landry et al, 1990) and this accounted
for 33–69% of all recurrences (Gunderson and Sosin, 1982; Landry
et al, 1990; Maehara et al, 2000; Yoo et al, 2000). These wide
recurrence rates are caused by the different criteria used for
recurrence, and the recurrence rates of clinical series are lower
than those of reoperation or autopsy studies. In our study, patterns
of failure were analysed according to the radiation field.
Locoregional recurrence developed in 16% of all treated patients,
and local and regional recurrences comprised 13 and 22% of all
recurrences. Some clinical series have reported similar results.
According to Yoo et al, local and regional recurrences were 18 and
13% of all recurrences, and Maehara et al reported a local
recurrence of 22% and a regional recurrence of 12%, as
percentages of all recurrence. These two studies are worthy of
note because the extent of surgery was D2 gastrectomy, as in the
present study. Though their studies were clinically based, the
relatively low rates of locoregional or regional recurrence observed
may be related to extended lymph node dissection. However,
analysed patients were selected from all recurrent patients, and no
statement was made concerning locoregional recurrence among
resected patients. Therefore, we can say that locoregional
recurrence accounts for about one-third of total recurrences in
Table 4 The patterns of failure according to clinicopathological factors
Total recurrence Local recurrence Regional recurrence Distant metastasis
Type of operation
TG (n¼116) 61/116 (53%) 9/116 (8%) 19/116 (16%) 53/116 (46%)
STG (n¼175) 53/175 (30%) 11/175 (6%) 16/175 (9%) 48/175 (27%)
P 0.0001 ns ns 0.001
Location of tumour
Distal (n¼150) 57/150 (38%) 10/150 (7%) 23/150 (15%) 52/150 (35%)
Middle (n¼123) 43/123 (35%) 8/123 (7%) 7/123 (6%) 38/123 (31%)
Proximal (n¼15) 11/15 (73%) 2/15 (13%) 4/15 (27%) 8/15 (53%)
Whole (n¼3) 3/3 (100%) 0/3 (0%) 1/3 (33%) 3/3 (100%)
P 0.049 ns ns ns
T stage
T1 (n¼25) 1/25 (4%) 1/25 (4%) 1/25 (4%) 1/25 (4%)
T2 (n¼116) 30/116 (26%) 6/116 (5%) 11/116 (10%) 25/116 (22%)
T3 (n¼143) 77/143 (54%) 10/143 (7%) 21/143 (15%) 70/143 (49%)
T4 (n¼7) 6/7 (86%) 3/7 (43%) 2/7 (29%) 5/7 (71%)
P o0.0001 0.045 0.033 o0.0001
N stage
N0 (n¼28) 6/28 (21%) 2/28 (7%) 1/28 (4%) 5/28 (18%)
N1 (n¼135) 33/135 (24%) 6/135 (4%) 9/135 (7%) 30/135 (22%)
N2 (n¼83) 40/83 (48%) 5/83 (6%) 12/83 (15%) 34/83 (41%)
N3 (n¼45) 35/45 (78%) 7/45 (16%) 13/45 (29%) 32/45 (71%)
P o0.0001 0.06 o0.0001 o0.0001
TNM stage
IB (n¼35) 3/35 (9%) 2/35 (6%) 1/35 (3%) 2/35 (6%)
II (n¼72) 11/72 (15%) 2/72 (3%) 2/72 (3%) 11/72 (15%)
IIIA (n¼91) 37/91 (41%) 5/91 (6%) 13/91 (14%) 32/91 (35%)
IIIB (n¼46) 26/46 (57%) 4/46 (9%) 5/46 (11%) 22/46 (48%)
IV (n¼47) 37/47 (79%) 7/47 (15%) 14/47 (30%) 34/47 (72%)
P o0.0001 0.02 o0.0001 o0.0001
TG¼total gastrectomy; STG¼subtotal gastrectomy.
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lsome clinical series, but it is difficult to conclude that similar
locoregional recurrence rates mean no need for adjuvant radio-
therapy. In our study, local recurrence was 7% and regional
recurrence was 12% for all treated patients.
In most studies that have analysed the patterns of failure, the
most common local failure site was the anastomosis or stump.
Landry et al reported that the recurrence rate of anastomosis was
25% in all patients. In subtotal gastrectomy patients, Papachristou
and Fortner reported that the remnant stomach was the highest
local recurrence site, with a 22% recurrence rate. According to our
data, recurrences at the anastomosis site and at the remnant
stomach were only 5% (16 out of 291) and 2% (four out of 175),
respectively. These low local recurrence rates might be due to
surgical factors or adjuvant treatment.
Many risk factors for locoregional recurrence have been
reported and the degree of gastric wall penetration has been
related to locoregional recurrence (Gunderson and Sosin, 1982;
Landry et al, 1990; Maehara et al, 2000; Yoo et al, 2000). This was
also observed in the present study and the invasion depth of
tumour correlated to all types of recurrences. The relation between
invasion depth and recurrence results from the abundant
lymphatic and vascular vessels in the gastric wall and tumour
extension by these routes (Lehnert et al, 1985). Otherwise, the
number of involved lymph nodes was found to be correlated to
regional recurrence and distant metastasis, but not to local
recurrence. Multivariate analysis showed that tumour invasion
more than the serosa or lymph node metastasis are risk factors for
total recurrence. That is, patients with T3, T4 and/or lymph node
metastasis could be candidates for adjuvant radiotherapy or
chemoradiotherapy.
The purpose of this study was to analyse the patterns of failure
after postoperative adjuvant chemoradiotherapy after gastrectomy
with D2 lymph node dissection, and determine whether adjuvant
radiotherapy reduces locoregional recurrence and increases
survival. Our study is based on clinical and radiological examina-
tions and is not a randomised study. Therefore, there is a
possibility of underestimating the recurrence pattern, and it is
difficult to conclude that postoperative chemoradiotherapy could
affect the recurrence pattern or survival after curative resection in
gastric adenocarcinoma. However, this is the first study to analyse
the patterns of failure after chemoradiotherapy in patients with
gastrectomy and D2 lymph node dissection. Locoregional recur-
rence developed in 16% of all patients, and, excepting patients with
T4 or N3, less than 15% of the local or regional recurrences
developed (Table 4). We do not know whether these recurrence
results are due to surgical extent, which included extended lymph
node dissection or adjuvant chemoradiotherapy, or both. How-
ever, the results of low locoregional recurrence rates could give a
clue as to which subset of patients could be helped by adjuvant
radiotherapy after gastrectomy with D2 lymph node dissection.
Therefore, to draw any conclusion on the role of adjuvant
radiotherapy in gastric adenocarcinoma with D2 gastrectomy, a
randomised study is needed.
Initially, our study was designed as a randomised trial, but we
failed to achieve this because most patients wanted adjuvant
treatment. If we could have completed this trial, we would have
been able to draw more precise conclusions about the role of
adjuvant treatment. However, given this limitation, our study
shows that postoperative chemoradiotherapy may be feasible, that
it has an acceptable toxicity and that the locoregional recurrence
rate was 16%. To determine the role of adjuvant chemoradiother-
apy, we are preparing a matched pair study between an adjuvant
chemoradiotherapy group and a surgery alone group. In addition,
we plan to undertake a randomised trial to compare adjuvant
chemoradiotherapy and chemotherapy alone in patients with
gastric adenocarcinoma after D2 gastrectomy.
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